Login / Signup

Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium.

Steven G DuBoisMeaghan P GrangerSusan GroshenDenice Tsao-WeiLingyun JiAnasheh ShamirianScarlett CzarneckiFariba GoodarzianRachel BerkovichHiroyuki ShimadaJudith G VillablancaKieuhoa T VoNavin R PintoYael P MosseJohn M MarisSuzanne ShustermanSusan L CohnKelly C GoldsmithBrian D WeissGregory A YanikClare J TwistMeredith S IrwinDaphne A Haas-KoganJulie R ParkAraz MarachelianKatherine K Matthay
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Vorinostat and MIBG is likely the arm with the highest true response rate, with manageable toxicity. Vincristine and irinotecan do not appear to improve the response rate to MIBG and are associated with increased toxicity.
Keyphrases
  • open label
  • oxidative stress
  • acute myeloid leukemia
  • placebo controlled
  • double blind
  • multiple myeloma
  • randomized controlled trial
  • histone deacetylase
  • study protocol
  • oxide nanoparticles